A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.

NCT07470853
clinicaltrials.gov
Phase
Phase 1
clinicaltrials.gov
Recruitment status
Recruiting
clinicaltrials.gov
Participants
265
clinicaltrials.gov
Lead sponsor
Whitehawk Therapeutics, Inc.
clinicaltrials.gov
Start date
2026-03-15
clinicaltrials.gov
Number of sites
12
clinicaltrials.gov

Summary
HWK-016-101 is a multicenter, open-label, first-in-human (FIH) Phase 1 study evaluating HWK-016, a targeted antibody-drug conjugate (ADC) in adult participants with advanced or metastatic solid tumors. The study employs a dose escalation and dose expansion design without a control group. The study consists of 2 parts (Part A: monotherapy and Part B: combination therapy with bevacizumab); each part has 2 phases, Phase 1a (dose escalation) and Phase 1b (dose expansion). Enrollment to Part A (Phase 1a and Phase 1b) will include ovarian and endometrial cancers. Enrollment to Part B (Phase 1a and Phase 1b) will include ovarian cancer only. A subsequent protocol amendment may evaluate additional tumor types.
clinicaltrials.gov
Short title
A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
clinicaltrials.gov
Official title
A Phase 1 First-in-Human Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
clinicaltrials.gov

Control arm
Open label
clinicaltrials.gov
Registry reports results
No
clinicaltrials.gov
Listing at source
Listed
clinicaltrials.gov
Recruitment status
Recruiting
clinicaltrials.gov
Phase
Phase 1
clinicaltrials.gov
Study type
Interventional
clinicaltrials.gov

Completion date
2028-02-01
clinicaltrials.gov
First posted
2026-03-13
clinicaltrials.gov
Registry last updated
2026-08-18
clinicaltrials.gov
Primary completion date
2028-02-01
clinicaltrials.gov
Start date
2026-03-15
clinicaltrials.gov

Participants
265
clinicaltrials.gov
Participant count basis
Estimated
clinicaltrials.gov
Planned participants
265
clinicaltrials.gov
Protocol amendments
0
clinicaltrials.gov
Number of sites
12
clinicaltrials.gov

Data monitoring committee
Yes
clinicaltrials.gov
Registry sponsor category
Industry
clinicaltrials.gov
Lead sponsor
Whitehawk Therapeutics, Inc.
clinicaltrials.gov
Source registry
ClinicalTrials.gov
clinicaltrials.gov

Registry ID
NCT07470853
clinicaltrials.gov
ClinicalTrials.gov ID
NCT07470853
clinicaltrials.gov
Registry record
Open registry record
clinicaltrials.gov

Allocation
Not randomised
Model
Sequential
Purpose
Treatment
Masking
No masking
Sources for study design
clinicaltrials.gov

  1. Determine Maximum Tolerated Dose (MTD)

    Timeframe: From Cycle 1, Day 1 Until Cycle 1, Day 21 (21-day cycles)

    Determine the highest dose of HWK-016 that can be administered without signs of toxicity, measured at the end of Cycle 1(21-day cycle) by: Incidence and severity of Adverse Events (AE). Incidence of Dose-Limiting Toxicities (DLT). Incidence of Serious Adverse Events (SAE). Evaluate the safety and tolerability of HWK-016 at the selected RDE(s) determined from Phase 1a, as monotherapy (Part A) in participants with ovarian and endometrial cancers and in combination therapy with bevacizumab (Part B) in participants with ovarian cancer

  2. Determine Maximum Administered Dose (MAD)

    Timeframe: From Cycle 1, Day 1 to Cycle 1, Day 21 (21-day cycles) until the MTD is reached.

    Determine the highest dose of HWK-016 administered during the dose escalation part of the study, measured at the end of Cycle 1 (21-day cycle) by: Incidence and severity of Adverse Events (AE). Incidence of Dose-Limiting Toxicities (DLT). Incidence of Serious Adverse Events (SAE). Evaluate the safety and tolerability of HWK-016 at the selected RDE(s) determined from Phase 1a, as monotherapy (Part A) in participants with ovarian and endometrial cancers and in combination therapy with bevacizumab (Part B) in participants with ovarian cancer

  3. Determine Recommended Dose For Expansion (RDE)

    Timeframe: From Cycle 1, Day 1 to Cycle 1, Day 21 (21-day cycle) until MTD is identified.

    Determine the dose of HWK-016 that will be recommended for further study within the tumor types studied in this clinical trial, measured at the end of Cycle 1, Day 21 (21-day cycle) by: Incidence and severity of Adverse Events (AE). Incidence of Dose-Limiting Toxicities (DLT). Incidence of Serious Adverse Events (SAE). Evaluate the safety and tolerability of HWK-016 at the selected RDE(s) determined from Phase 1a, as monotherapy (Part A) in participants with ovarian and endometrial cancers and in combination therapy with bevacizumab (Part B) in participants with ovarian cancer.

  1. Characterize the Volume of Distribution (Vd) of HWK-016 (ADC, total antibody, CPT116, and CPT119)

    Timeframe: Cycle 1 and Cycle 4 (21-day cycles)

    Pharmacokinetic analysis of HWK-016 in human subjects

  2. Maximum Concentration - Cmax of HWK-016 (ADC, total antibody, CPT116, and CPT119)

    Timeframe: At Cycle 1 and Cycle 4 - (21-day cycles)

    Maximum amount of study drug and drug components in blood following infusion.

  3. Time to Maximum Concentration (Tmax) of HWK-016 (ADC, total antibody, CPT116, and CPT119)

    Timeframe: Cycle 1 and Cycle 4 - (21-day cycles)

    Time to reach maximum concentration of drug and drug components in blood following infusion.

  4. Area Under the Concentration Time Curve (AUC) for HWK-016 (ADC, total antibody, CPT116, and CPT119)

    Timeframe: Cycle 1 and Cycle 4 - (21-day cycles

    The total area under the concentration time curve of study drug and drug components following infusion

  5. T1/2 - Half-life of HWK-016 (ADC, total antibody, CPT116, and CPT119)

    Timeframe: Cycle 1 and Cycle 4 - (21-day cycles)

    Time for 1/2 of the infused drug to be eliminated/metabolized

  6. Clearance (CL)

    Timeframe: Cycle 1 and Cycle 4 (21-day cycles)

    Measured rate at which HWK-016 is cleared from the blood following infusion.

  7. Assess ADA (Anti drug antibody) against HWK-016

    Timeframe: Every cycle from Cycle 1, Day 1 (21-day cycles) until 30 days past the last dose of study drug for up to 24 months.

    Using a blood test, determine the risk of developing anti-drug antibodies against HWK-016 following infusion in human patients.

  8. Evaluate the Overall Response Rate (ORR

    Timeframe: From Cycle 1, Day 1 (21-day cycles), every 6-weeks for the first 4 assessments and then every 6 weeks for up to 24 months until disease progression or 24 months, whichever comes first.

    Measure the response rate to the study drug by CT-scans evaluated using RECIST1.1. Evaluate preliminary antitumor activity of HWK-016 at the selected RDE(s) determined from Phase 1a, as monotherapy (Part A) in participants with ovarian and endometrial cancers and in combination therapy with bevacizumab (Part B) in participants with ovarian cancer by RECIST Version 1.1

  9. Evaluate Overall Survival (OS).

    Timeframe: From Cycle 1, Day 1 (21-day cycles) until death or 24 months, whichever comes first.

    Measure how long a patient lives following treatment with HWK-016. Evaluate the Overall Survival at the selected RDE(s) determined from Phase 1a, as monotherapy (Part A) in participants with ovarian and endometrial cancers and in combination therapy with bevacizumab (Part B) in participants with ovarian cancer

  10. Evaluate the Duration of Response (DoR) to HWK-016

    Timeframe: From Cycle 1, Day 1 (21-day cycles) until disease progression or 24 months, whichever comes first.

    Measure the time from evidence of response by CT-scan until evidence of progression of cancer. Evaluate the Duration of Response at the selected RDE(s) determined from Phase 1a, as monotherapy (Part A) in participants with ovarian and endometrial cancers and in combination therapy with bevacizumab (Part B) in participants with ovarian cancer

  11. Evaluate Progression-free Survival (PFS)

    Timeframe: From Cycle 1, Day 1 (21-day cycles) infusion to End of Study (up to 24 months)

    Measure the time from the first infusion of HWK-007 until evidence of cancer progression is detected. Evaluate the Progression Free Survival at the selected RDE(s) determined from Phase 1a, as monotherapy (Part A) in participants with ovarian and endometrial cancers and in combination therapy with bevacizumab (Part B) in participants with ovarian cancer

  12. Evaluate Disease control Rate (DCR)

    Timeframe: From Cycle 1, Day 1 (21-day cycles) infusion to End of Study (up to 24 months

    Measure the time from Cycle 1, Day 1 that cancer does not worsen by RECIST1.1 criteria. Evaluate the Disease Control Rate at the selected RDE(s) determined from Phase 1a, as monotherapy (Part A) in participants with ovarian and endometrial cancers and in combination therapy with bevacizumab (Part B) in participants with ovarian cancer

  13. Time to Response (TTR)

    Timeframe: From Cycle 1, Day 1 (21-day cycles) until End of Study or 24 months, whichever comes first

    Time from Cycle 1, Day 1 infusion of HWK-016 until evidence of response via CT scan according to RECIST1.1 criteria. Evaluate the Time to Response at the selected RDE(s) determined from Phase 1a, as monotherapy (Part A) in participants with ovarian and endometrial cancers and in combination therapy with bevacizumab (Part B) in participants with ovarian cancer

Sources for outcomes
clinicaltrials.gov

Sex
All
Age groups
Adults, Older adults
Minimum age
18 Years
Healthy volunteers
No

  • Have one of the following solid tumor cancers:

    1. Monotherapy escalation, backfill and expansion cohorts:

      1. Endometrial Carcinoma
      2. Ovarian Cancer

    2. Combination Escalation, Backfill and Expansion Cohorts a. Ovarian Cancer

  1. Individual with known or suspected uncontrolled central nervous system (CNS) metastases
  2. Individual with history of carcinomatous meningitis
  3. Individual with active uncontrolled systemic bacterial, viral, fungal, or parasitic infection
  4. Individual with evidence of corneal keratopathy or history of cornea transplant
  5. Any serious unresolved toxicities from prior therapy
  6. Significant cardiovascular disease
  7. Prolongation of QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥ 470 milliseconds (ms)
  8. History of pneumonitis/interstitial lung disease
  9. Individuals who are pregnant, breastfeeding or plan to breastfeed during study or within 30 days of last dose of study intervention
Sources for eligibility
clinicaltrials.gov

  • University of Arkansas - Winthrop P. Rockefeller Cancer InstituteLittle Rock, United StatesRecruiting
  • START - Los AngelesLos Angeles, United StatesRecruiting
  • SCRI - Florida Cancer SpecialistsSarasota, United StatesRecruiting
  • St. Francis Medical Center (OSF Healthcare)Peoria, United StatesRecruiting
  • Karmanos Cancer CenterDetroit, United StatesNot yet recruiting
  • Start - NyLong Island City, United StatesRecruiting
  • Memorial Sloan Kettering Cancer CenterNew York, United StatesNot yet recruiting
  • Atrium Health - Wake ForestCharlotte, United StatesNot yet recruiting
  • Ohio State University Wexner Medical CenterColumbus, United StatesRecruiting
  • SCRI - Sydney Kimmel Cancer Center - Jefferson HealthPhiladelphia, United StatesRecruiting
  • SCRI - Mary Crowley Cancer ResearchDallas, United StatesRecruiting
  • START MountainSalt Lake City, United StatesRecruiting
Sources for sites
clinicaltrials.gov

Related records

Drugs (2)

Collaborators (1)

Lead sponsors (1)

Conditions (2)

Targets (2)